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Abstract: Although rapid diagnostic testing is essential in suspi-
cious peripheral lymphadenopathy, delays in accessing them can be
considerable. We investigated the usefulness of an internist-led
outpatient quick diagnosis unit (QDU) in assessing patients with
unexplained peripheral lymphadenopathy, focusing on the charac-
teristics, diagnostic, and treatment waiting times of those with
malignancy. Patients aged ³18 years, consecutively referred from 12
primary health care centers (PHCs) or the emergency department
(ED) for unexplained peripheral lymphadenopathy, were pros-
pectively evaluated during 7 years. Diagnostic investigations were
done using a predefined study protocol. Three experienced cyto-
pathologists performed a fine-needle aspiration cytology (FNAC)
systematic approach of clinically suspicious lymphadenopathy with
cytomorphology and immunophenotyping analyses. We evaluated
372 patients with a mean age (SD) of 45.3 (13.8) years; 56% were
women. Malignancy was diagnosed in 120 (32%) patients, including
81 lymphomas and 39 metastatic tumors. Metastatic lymphadeno-
pathy was diagnosed by FNAC in all 39 patients and the primary
tumor site was identified in 82% of them when cytomorphology and
immunocytochemistry were combined. A correct diagnosis of
lymphoma was reached by FNAC in 73% of patients. When
accepting “suspicious of” as correct diagnosis, the FNAC diagnosis
rate of lymphoma increased to 94%. Among patients with malig-
nancy, FNAC yielded 1.3% of false negatives and no false positives.
All patients with an FNAC report of correct or suspicious lymphoma
underwent a surgical biopsy, as it is a mandatory requirement of the
hematology department. Mean times from first QDU visit to FNAC
diagnosis of malignancy were 5.4 days in metastatic lymphadeno-
pathy and 7.5 days in lymphoma. Mean times from receiving the
initial referral report to first treatment were 29.2 days in metastatic
lymphadenopathy and 40 days in lymphoma. In conclusion, a distinct
internal medicine QDU allows an expeditious, agile, and prearranged
system to diagnose malignant peripheral lymphadenopathy. Because
of the close collaboration with the cytopathology unit and the FNAC
methodical approach, diagnostic and treatment waiting times of
patients with malignancy fulfilled national and international time
frame standards. This particular diagnostic delivery unit could help
overcome the difficulties facing PHC, ED, and other physicians
when trying to provide rapid access to investigations to patients with
troublesome lymphadenopathy.
(Medicine 93(16):e95)
Abbreviations: CI = confidence interval, ED = emergency
department, FNAC = fine-needle aspiration cytology, HL =
Hodgkin lymphoma, NHL = non-Hodgkin lymphoma, NHS =
National Health Service, PHC = primary health care center, QDU
= quick diagnosis unit, QED = quick and early diagnosis, RR =
risk ratio.
INTRODUCTION
Peripheral lymphadenopathy has a wide differential diag-nosis and causes concern among patients and doctors
alike due to the possibility of a missed or delayed diagnosis
of malignancy.1 Compared with the general population,
patients with enlarged lymph nodes were recently reported to
have a significantly increased risk of hematological and solid
cancer during follow-up.2 Therefore, especially in patients
with troublesome peripheral lymphadenopathy, quick diag-
nostic testing can be essential.
In countries such as Spain, where 90% of hospitals are
public, diagnostic tests such as CT scans and endoscopies
may take several weeks or even months when ordered by
primary health care center (PHC) physicians. Furthermore,
patients requiring cytological or histological studies can only
be assessed in the hospital setting, unless the patient has a
private provider. However, although most patients with
peripheral lymphadenopathy are referred to the outpatient
clinics of the reference hospital to speed up diagnostic
procedures,3–5 even in this setting, some diagnostic examina-
tions may take several weeks. In some cases, PHC physicians
refer patients directly to the emergency department (ED),
hoping to gain faster access to diagnostic investigations.6,7
Outpatient quick diagnosis units (QDUs), based in
hospitals and headed by internists, are a proposed solution
for delays in the diagnosis of patients with suspected serious
disease, most notably cancer, decreasing PHC referrals to ED
and helping avoid hospitalizations for diagnostic workup.
Although still little known today, these types of units have
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been tested and exist in Europe, and they have been
essentially studied in Spain.6–9 Because of their dynamic,
agile functioning and the savings generated, QDUs are
viewed as having strong implications in Spain and possibly
other public funded health systems such as the UK, where
outpatient practice is also under intense pressure.7–9 Explo-
ring the potential implications of implementing QDU in the
United States, US investigators recently argued that because
most primary care physicians in this country are unlikely to
provide regular and frequent access to unscheduled care,
these units could provide an innovative healthcare diagnostic
service with the potential to attain the objective of cost-
effective high quality for everyone.9
Patients with new onset unexplained peripheral lymphade-
nopathy, including those with subsequent confirmation of
malignancy, may have few or no associated general symp-
toms,1,10–12 and are therefore especially suitable for QDU
evaluation. However, no study has assessed the significance of
this model for the diagnosis and management of this condition.
Encouraged by our initial fruitful collaboration with the
cytopathology unit of our hospital, we decided to investigate
the convenience and usefulness of a QDU of a tertiary,
university hospital in Barcelona in evaluating patients
referred for unexplained peripheral lymphadenopathy, focu-
sing on the characteristics, diagnostic, and treatment waiting
times of those with metastatic lymphadenopathy and hemato-
logical malignancies.
MATERIALS AND METHODS
The Unit
Patients with potentially serious disease who are well
enough to travel to the QDU and the hospital diagnostic
services on an outpatient basis are evaluated at the QDU,
sited in an 870-bed third level hospital in Barcelona (Spain)
with a reference population of almost 550,000. Most referrals
come from the hospital ED and a dozen PHC. The charac-
teristics, functioning, and referral criteria of the unit have
been reported elsewhere.6,7
Study Design and Population
We prospectively evaluated patients aged ³18 years,
who were consecutively referred to the QDU from PHC or
ED between July 2006 and September 2013 because of
unexplained peripheral lymphadenopathy. Inclusion criteria
were peripheral lymphadenopathy detected by the referring
physician on physical examination or imaging studies (eg,
ultrasonography) and reported as the main reason for referral
to QDU, and no apparent diagnosis after at least 1 visit at
the PHC or ED. Patients in whom lymphadenopathy resolved
or was not identified at the first QDU visit and patients lost
to follow-up were excluded. The study was approved by the
Hospital Clınic research ethics committee. Informed consent
was obtained from all patients included.
Diagnostic Protocol of Unexplained Peripheral
Lymphadenopathy
Each patient was evaluated by the attending physician
of the QDU, a consultant internist, who did a complete
anamnesis and physical examination and initiated a diag-
nostic study of unexplained peripheral lymphadenopathy
according to a specific protocol. To objectively assess the
size of the enlarged lymph node and monitor any growth or
reduction, a plastic caliper was used to measure its surface
palpability (long and short axes). When there were clinical
doubts about the significance of a lymph node, an ultra-
sonography of the region was carried out.
Different protocol-driven diagnostic tests were per-
formed according to clinical presentation and characteristics
of lymphadenopathy. Laboratory tests included, among
others, acute phase reactants (C-reactive protein and erythro-
sedimentation rate), hemogram (total leukocytes, manual
white blood cell count, hemoglobin, hematocrit, and plate-
lets), liver function tests, serum lactate dehydrogenase, serum
total proteins and protein electrophoresis, microbiologic
serologies (eg, IgM and IgG for cytomegalovirus, Epstein–
Barr virus, Toxoplasma gondii, and human parvovirus B19),
human immunodeficiency virus testing, serum β2 micro-
globulin, and serum tumor markers including carcino-
embryonic antigen, prostate-specific antigen (men), cancer
antigen 15-3 (women), cancer antigen 19-9, neuron-specific
enolase, and cancer antigen 125.
During successive visits, results of initial diagnostic
studies were checked over and the course of disease was
evaluated. As predefined by the study protocol, when a
diagnosis had not been reached, additional investigations
were performed as appropriate in accordance with the results
of the previous ones and the clinical course of disease.
Cytological and Histological Investigations
Fine-needle aspiration cytology (FNAC) was carried out
according to the characteristics, size, and site of lymphadeno-
pathy. In general, regardless of size, any patient with hard
and fixed lymphadenopathy underwent an FNAC. When
various lymph nodes were palpable, the largest, most
suspicious, and accessible was chosen.
The FNAC procedure was performed on 2 days a week
by a team of 3 cytopathologists in a specific cytology room.
The cytopathologist who performed the FNAC also examined
the samples. The procedure was performed with 23-G or
25-G needles and the quality of the sample obtained was
evaluated on-site. One-half to two-thirds of the slides
obtained in the first needle pass were quickly stained
(Panoptic; Grifols, Barcelona, Spain) and immediately exa-
mined. When infection was suspected, staining, cultures, and
polymerase chain reaction on FNAC specimens were
performed. When the smear favored the diagnosis of epi-
thelial metastasis, 1 or 2 additional passes were repeated to
obtain material for the cellblock preparation for immunocyto-
chemical studies. If lymphoma was suspected after the on-
site evaluation, further passes were repeated to obtain
material for flow cytometry analysis. Cytology and flow
cytometry samples were labeled as insufficient if the material
was scarce or autolytic. Flow cytometry and immunocyto-
chemical studies were done in the hospital immuno-
phenotyping unit. Patients with a correct or suspicious
diagnosis of lymphoma by FNAC underwent a surgical
biopsy (usually at a later stage), as it is a requirement of the
hematology department.
For difficult-to-access lymphadenopathy, FNAC was
ultrasound guided by a radiologist and the material was also
assessed by a cytopathologist.
Onward Referrals and Follow-Up
Patients with obvious or suspicious lymphoma by FNAC
were immediately referred to the hematology department,
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whether or not the mandatory biopsy had already been
performed. Staging of lymphoma was not systematically done.
Patients with solid malignancies were referred to the oncology
department upon receipt of the FNAC report. Patients with
reactive lymphadenopathy by FNAC and those with undiag-
nosed lymphadenopathy in whom FNAC was considered
unnecessary were reassured and discharged from the QDU.
These patients were reassessed at 2, 4, and 6 months after
discharge to check any change in lymphadenopathy.
Database
Details on patients’ demographic and epidemiological
data, past history of malignancies, previous administration
of medications, clinical presentation and course of disease,
associated signs and symptoms, and laboratory, imaging,
endoscopic, FNAC, and biopsy results were prospectively
registered in a database. We also tabulated the source of
referral; number and date of QDU visits; waiting times
between visits; time to diagnosis; type, number, and date of
diagnostic tests; final diagnosis; onward referral; and
follow-up. For lymphadenopathy, we recorded the presence
of local symptoms, duration from onset, size (³1 cm or
<1 cm), characteristics (soft, mobile, well demarcated,
tender, hard, and fixed), number [localized (only 1 anatomic
region of nodal drainage involved) or generalized (³2
anatomic regions)], and site.
Statistical Analysis
A descriptive analysis was made. We used stepwise
logistic regression to determine the risk of malignancy in
enlarged lymph nodes, including the following independent
variables: age, sex, ethnicity, fever, weight loss, night sweats,
duration, characteristics, size, site, and number of lymphade-
nopathies. The risk ratios (RRs) with 95% confidence
intervals (CIs) for the various factors were calculated. A P
value <0.05 was considered statistically significant. Data
analysis was made using the SAS v.9.1 statistical package
(SAS Institute Inc, Cary, NC).
RESULTS
A total of 394 patients were referred to the QDU during
the study period. Their mean age (SD) was 44.9 (13.1) years
and 220 (56%) were women. Twenty-two patients were
excluded, 6 were lost to follow-up after the first visit, and 16
had no palpable lymphadenopathy on the first visit.
General Characteristics of the Study Population
We evaluated 372 patients, mostly white, with a mean
age of 45.3 years (range, 18–92 years) and 207 (56%)
women. Five patients had a history of malignancy. Patients
were referred from PHC (64%) and ED (36%). The mean
time from receiving the referral report to the first QDU visit
was longer in patients referred from PHC than ED (Table 1).
The mean number of QDU visits per patient was 3.4 (1.2)
(median [P25;P75] 2.9 [2.6;3.2]). Table 2 shows the accom-
panying signs and symptoms on presentation and Table 3 the
diagnostic examinations performed.
Final Diagnoses
The most frequent diagnosis was reactive lymphadeno-
pathy as diagnosed by FNAC in 110 (30%) patients (mean age
38 [10.3] years; median 39.8 [37.1;43] years). Ninety-one
(24%) patients had infections, including viral infections in 45
(12%) patients (mean age, 32 [9.2] years; median, 34.1
[31;36.5] years) and tuberculosis lymphadenitis in 26 (7%)
patients (mean age, 34.1 [10.6] years; median, 36 [34.2;39.1]
years). A marked lymphocytosis (>50% of leukocytes) with
atypical cells comprising >10% of leukocytes was observed in
40% of patients with viral infections and 38% of those with
toxoplasmosis. Malignancy was diagnosed in 120 (32%)
patients, including 81 lymphomas and 39 metastatic tumors
(Table 4). The mean age of patients with metastatic tumors
was 62.6 (16.1) years (median, 64.9 [60.1;68] years). Tables 4
and 5 list the specific diagnoses and the characteristics of
lymphadenopathy in the main diagnostic groups, respectively.
Cytological and Histological Results
Overall, FNAC was performed in 268 (72%) patients
and biopsy in 81 (22%) patients. Based on the characteristics
of lymphadenopathy and clinical manifestations, 104 (28%)
patients did not undergo FNAC or biopsy.
TABLE 1. Main Characteristics of Study Patients
Patients
(n¼ 372)
Age 45.3 (13.8),
48 (43;52.4)
Female 207 (56)
Male 165 (44)
Ethnicity
White 333 (90)
Black 7 (2)
Asian (Indian, Pakistani, Bangladeshi) 18 (5)
Chinese 3 (1)
Philippine 2 (1)
Indian American ancestry (Latin
American countries)
9 (2)
Past history of malignancy 3 (1)
Hematological malignancy 2 (1)
Solid tumors
Referral sources
ED 134 (36)
PHC 238 (64)
Waiting time for first QDU visit, d*
ED 3.2 (1.3),
2.8 (2.2;3.4)
PHC 5.2 (1.7), 4.7 (4;5.4)
Number of QDU visits
First visits 372
Successive visits 2.4 (0.9),
1.9 (1.7;2.1)
Time to diagnosis, d* 9.6 (2.9),
9.0 (8.2;9.8)
Destination
PHC 213 (57)
Outpatients 148 (40)
Admission 7 (2)
Other 4 (1)
Data expressed as mean (SD) and median (25th–75th percentiles)
or number (percentage). ED¼ emergency department, PHC¼ public
health care center, QDU¼ quick diagnostic unit.
*Consecutive days, including weekends and holidays.
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Reactive lymphadenopathy was diagnosed by FNAC in
110 patients: 92 by both cytomorphology and flow cyto-
metry, 14 by flow cytometry (suspicious cytomorphology
findings in 7 and insufficient material for cytomorphology in
7), and 4 by cytomorphology (insufficient material for flow
cytometry in all 4).
Metastatic lymphadenopathy was diagnosed by FNAC in
39 patients, which included 5 suspicious cases. In 37/39 (95%)
patients with metastatic lymphadenopathy, FNAC was ordered
at the first QDU visit. Material was sufficient for evaluation of
cytomorphology or cytomorphology and immunocytochemistry
in all patients. Combining both approaches, the primary tumor
site was identified in 32 (82%) patients, which included 4
suspicious cases (2 non-small-cell lung carcinoma, 1 small-cell
lung carcinoma, and 1 gastric adenocarcinoma) (Table 4).
Cases of non-Hodgkin lymphoma (NHL) (n¼ 55) and
Hodgkin lymphoma (HL) (n¼ 26) were fully subtyped by
biopsy. In 78/81 (96%) patients with lymphoma, FNAC was
ordered at the first QDU visit. Among all 81 patients with
lymphoma, 17 (21%) had a suspicious diagnosis and 1 had
reactive changes by FNAC. Material was insufficient for
cytomorphology in 5% of cases (all HL) and for flow cytometry
in 21% (12% NHL and 9% HL). By combining cytomorphology
and flow cytometry results, a correct diagnosis of lymphoma
was made in 73% of cases. When accepting “suspicious of” as
correct diagnosis, the diagnosis rate increased to 94% (Table 6).
The different subtypes of NHL according to cytomorphology
and flow cytometry findings are shown in Table 6. Fifty-four
percent of patients with HL were correctly diagnosed by FNAC.
Histopathological diagnoses of HL included 15 cases of nodular
sclerosis classical HL, 6 of mixed cellularity classical HL, 3 of
lymphocyte-rich classical HL, and 2 of nodular lymphocyte
predominant HL.
Waiting Times in Patients With Malignancy
In patients with malignancy, the mean wait from
receiving the initial referral report to the first QDU visit was
2.9 (1.1) days (median, 2.5 [1.9;3.2] days) in patients
referred from ED and 4.8 (1.6) days (median, 4.4 [3.6;5.2]
TABLE 3. Main Diagnostic Investigations
Patients (n¼ 372)
Chest x-ray 312 (84)
Abdominal ultrasonography 40 (11)
Computed tomography 107 (29)
Magnetic resonance 14 (4)
Bone marrow aspiration 22 (6)
Bone marrow biopsy 5 (1)
Mammography 14 (4)
Endoscopic ENT examination 13 (4)
Ultrasound of the thyroid 11 (3)
Fiberbronchoscopy 7 (2)
Upper digestive endoscopy 16 (4)
Colonoscopy 12 (3)
Bone scintigraphy 13 (4)
Positron emission tomography 32 (9)
Data expressed as number (percentage). ENT¼ ear, nose, and throat.
TABLE 4. Final Diagnoses of Study Patients
Patients (n¼ 372)
Undiagnosed (nonspecific) lymphadenopathy 45 (12)
Reactive lymphadenopathy 110 (30)
Malignant diseases 120 (32)
Hematological malignancies 81 (22)
HL 26 (7)
NHL 55 (15)
Metastatic tumors 39 (11)
Non-small-cell lung carcinoma 8 (2)
Small-cell lung carcinoma 3 (1)
Head and neck squamous cell carcinoma 4 (1)
Breast carcinoma 5 (1)
Thyroid cancer 3 (1)
Melanoma 1 (0)
Gastric adenocarcinoma 3 (1)
Pancreatic adenocarcinoma 2 (1)
Endometrial cancer 1 (0)
Urothelial carcinoma 1 (0)
Prostatic adenocarcinoma 1 (0)
Unknown primary origin 7 (2)
Squamous carcinoma 2 (1)
Carcinoma 2 (1)
Neuroendocrine tumor 2 (1)
Adenocarcinoma 1 (0)
Infections 91 (24)
Viral infections 45 (12)
Cytomegalovirus 18 (5)
Epstein–Barr virus 15 (4)
Parvovirus B19 4 (1)
Human immunodeficiency virus 6 (2)
Human herpes virus type 6 2 (1)
Oral cavity infection* 4 (1)
Cutaneous infection* 4 (1)
Tuberculosis 26 (7)
Syphilis 4 (1)
Toxoplasmosis 8 (2)
Sarcoidosis 2 (1)
Benign lymph node tumors 2 (1)
Extranodal “lumps” 2 (1)
Data expressed as number (percentage). HL¼Hodgkin lymphoma,
NHL¼ non-Hodgkin lymphoma.
*Unknown microorganism.
TABLE 2. Accompanying Signs and Symptoms on
Presentation
Patients (n¼ 372)
Palpable liver 88 (24)
Splenomegaly 47 (13)
Fever 84 (23)
Weight loss 86 (23)
Night sweats 79 (21)
Sore throat 41 (11)
Rash 25 (7)
Generalized pruritus 12 (3)
Data expressed as number (percentage).
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days) in those referred from PHC. In addition, the mean time
from the first visit to the FNAC procedure was 2.1 (1.0)
days (median, 1.8 [1.5;2.0] days).
Regarding diagnosis, the mean time from the first visit
to the FNAC diagnosis was 5.4 (1.8) days (median, 4.9
[4.1;5.8] days) in metastatic lymphadenopathy. In lympho-
mas, the mean time between the first visit and the FNAC or
biopsy (when FNAC failed because of false negatives [ie,
reactive changes in 1 case] or insufficient material for
cytomorphology evaluation [ie, 4 HD cases]) diagnosis was
7.5 (2.5) days (median, 7 [6.0;8.1] days).
Following diagnosis and QDU discharge, the mean wait
for an appointment of an oncologist and a hematologist was
4.2 (1.6) days [median, 3.8 (3.3;4.2) days] and 3.3 (1.2) days
(median, 2.8 [2.3;3.4] days), respectively.
As mentioned, all patients with lymphoma underwent a
formal mandatory biopsy regardless of the FNAC diagnosis.
This biopsy was immediately ordered by the QDU attending
physician upon receipt of the FNAC diagnostic report and, in
order to save time, mostly performed after QDU discharge.
Specifically, the mean time between an FNAC report of
correct or suspicious lymphoma and the biopsy procedure in
all 76 patients with this diagnosis was 6.1 (2.2) days
(median, 5.6 [4.8;6.3] days), whereas the mean time between
the biopsy procedure and its diagnostic report was 5.7 (2.0)
days (median, 5.2 [4.8;5.6] days).
With regard to treatment, the mean time from the
FNAC (and biopsy in 5 lymphoma patients) report to the
first treatment (chemotherapy or radiotherapy) was 28.3 (3.7)
days (median, 27.2 [25.8;28.6] days) in patients with
lymphoma and 19.6 (3.1) days (median, 18.7 [17.6;19.8]
days) in those with metastatic lymphadenopathy.
Overall, the full mean time from receiving the initial
referral report to the first treatment was 40 (3.8) days
(median, 39.1 [37.5;40.7] days) in patients with lymphoma
and 29.2 (3.4) days (median, 28.0 [26.7;29.3] days) in
patients with metastatic lymphadenopathy.
Follow-Up of Patients With Nonmalignant
Lymphadenopathy
At 6 months of follow-up, lymphadenopathy was palpable
in only 8% of patients with reactive lymphadenopathy and in
9% with undiagnosed lymphadenopathy who did not undergo
FNAC. Palpable lymph nodes were all <1 cm and all patients
were symptom free.
Multivariate Analysis
Five independent factors were associated with malignant
lymphadenopathy: increasing age (RR¼ 1.31; 95% CI, 1.05–
1.67; P¼ 0.02), male sex (RR¼ 2.53; 95% CI, 1.54–3.93;
P¼ 0.01), size ³1 cm (RR¼ 4.43; 95% CI, 2.77–6.48;
P< 0.001), supraclavicular region (RR¼ 4.72; 95% CI,
3.02–6.79; P< 0.001), and hard and fixed characteristics
(RR¼ 15.36; 95% CI, 13.27–17.61; P< 0.001).
DISCUSSION
Although the incidence of peripheral lymphadenopathy in
the general population is low and estimated at 0.6% to 0.7%, the
prevalence of malignancy depends on the health care setting and
patients’ age, ranging from 0.4% in patients aged <40 years to
4% in those aged >40 years in primary care.1,10–12
In our QDU, purposely designed to evaluate patients with
potentially serious diseases, 32% of those referred for unex-
plained peripheral lymphadenopathy had malignancy (lympho-
mas in 68% and metastatic tumors in 33%), mostly diagnosed
by a first quick FNAC approach. In a 2003 study by Chau
et al10 of a UK rapid access lymph node diagnostic clinic, to
which patients were referred from PHC, the prevalence of
malignancy was 17% (95/550 patients) (lymphomas in 65%
and metastatic tumors in 31%). Although the general function-
ing of this unit was somewhat similar to ours, their patients
were initially assessed by medical oncologists,10 whereas QDU
patients were assessed by internists. A distinctive feature of
our QDU (and most Spanish internal medicine QDU) is that it
is not “monothematic” but several unrelated conditions, all of
them potentially associated with cancer, are evaluated includ-
ing, among others, enlarged lymph nodes, unintentional weight
loss, palpable abdominal masses, lung and/or pleural abnor-
malities suggestive of neoplasm, severe anemia, rectorrhagia,
and unexplained fever.6–8
The concept of quick and early diagnosis (QED) was
pioneered by Kendall et al13 in 1996 in The Lancet. These
authors described the suitability of a hospital QED unit in
the UK, mainly for patients with suspected malignancy
TABLE 5. Characteristics of Lymphadenopathy in Main Diagnostic Groups
Reactive
(n¼ 110)
Viral Infections
(n¼ 45)
Tuberculosis
(n¼ 26)
Lymphoma
(n¼ 81)
Metastatic
(n¼ 39)
Length of time present, wk 4.2 (1.1),
3.8 (3.2;4.3)
1.2 (0.7),
1 (0.7;1.2)
10.3 (1.8),
9.7 (9.1;10.5)
3.8 (1.0), 3.4
(2.9;3.9)
3.1 (0.9), 2.6
(2.4;2.9)
³1 cm 6 10 24 73 37
<1 cm 104 35 2 8 2
Localized 88 8 20 35 27
³2 regions 22 37 6 46 12
Soft, mobile, well demarcated 107 42 3 5 0
Hard, fixed 3 3 23 76 39
Head and neck 63 5 16 24 14
Supraclavicular 1 1 4 5 8
Axillary 10 0 0 3 4
Inguinal 14 2 0 3 1
Data expressed as mean (SD) and median (25th–75th percentiles) or number.
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referred from PHC. Patients underwent prompt diagnostic
workup without admission and were evaluated by different
consultants according to the reason for referral (eg, urologists
for hematuria or testicular swellings, endoscopists for
gastrointestinal bleeding, or breast surgeons for breast
lumps).13 A more elaborated conception was defined by our
group, and named the “quick diagnosis unit.”14 Although we
have reported that QDU is a cost-saving and efficient
alternative to conventional hospitalization for diagnostic
purposes,6–8 cancer represents the most common diagnosis in
Spanish QDU (18%–30% of cases).9
Instances of international and national proposals and
policies to speed up the diagnosis of cancer from suspicion
abound.15,16 Shortening the times between suspected and
confirmed diagnosis is a cancer health care priority of the
World Health Organization.17 The UK government in 2000 set
up the National Health Service (NHS) Cancer Plan, establish-
ing waiting time standard targets. For instance, PHC physi-
cians should “urgently” refer any patient with suspected
malignancy, including those with lymphadenopathy >1 cm
persisting for 6 weeks, to a hospital specialist within 2 weeks
for first assessment.18–20 Although far less ambitious and
elaborate than the UK NHS Cancer Plan, the 2006 (updated in
2010) Spanish Health System Cancer Strategy advocates a first
confirmatory test within 2 weeks of suspected malignancy.21
In our study, the mean wait from receiving the initial referral
report to the first QDU visit (where important diagnostic
decisions were made [eg, FNAC in ³95% of patients in about
2 days]) was short: nearly 3 days for ED referrals and 5 days
for PHC referrals. This wait was longer in patients referred
from PHC because these referrals require preappointment
checking by the QDU physician, whereas ED referrals do not.6
TABLE 6. Histopathological, Cytological, and Flow Cytometry Results in Patients With Lymphoma, Sampled by Surgical
Biopsy and FNAC
Cytology and Flow Cytometry Results
Lymphoma
(n¼ 81)
Histopathology
Diagnosis
Definitive
Diagnosis Suspicious of
Insufficient
Material for
Cytology
Insufficient
Material
for FC
NHL
n¼ 55
55/55 (100%)
Follicular lymphoma
n¼ 22
22/22 18/22 Follicular lymphoma 3/22 1 Reactive 5/22
DLBCL
n¼ 18
18/18 14/18 DLBCL 4/18 3/18
Small lymphocytic
lymphoma
n¼ 4
4/4 4/4 Small lymphocytic
lymphoma
Mantle cell lymphoma
n¼ 3
3/3 2/3 Mantle-cell lymphoma 1/3 1/3
Nodal marginal zone
lymphoma
n¼ 2
2/2 2/2 Marginal zone
lymphoma
Lymphoplasmacytic
lymphoma
n¼ 1
1/1 1/1 B-cell lymphoma
Burkitt lymphoma
n¼ 1
1/1 1/1 High-grade B-cell
lymphoma
Peripheral T-cell
lymphoma, NOS
n¼ 2
2/2 1/2 T-cell lymphoma 1/2 1/2
Angioimmunoblastic
T-cell lymphoma
n¼ 1
1/1 1/1 High-grade T-cell
lymphoma
Anaplastic large-cell
lymphoma, ALK positive
n¼ 1
1/1 1/1 High-grade T-cell
lymphoma
HL
n¼ 26
26/26 (100%) 14/26 HL 8/26 4/26 7/26
Overall insufficient sampling 4/81 (5%) 17/81 (21%)
Overall definitive diagnosis 81/81 (100%) 59/81 (73%) 76/81 (94%)
including “suspicious of”
ALK¼ anaplastic lymphoma kinase, DLBCL¼ diffuse large B-cell lymphoma, FC¼ flow cytometry, FNAC¼ fine-needle aspiration
cytology, HL¼Hodgkin lymphoma, NHL¼ non-Hodgkin lymphoma, NOS¼ not otherwise specified.
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The Spanish Cancer Strategy also promoted the estab-
lishment of circuits providing rapid access to diagnostic
resources to patients with well-founded suspicion of cancer.21
The UK Department of Health also realized that the most
important primary care priority in improving early diagnosis
was improved access to diagnostic tests,20 leading to a 2007
revision of the NHS Cancer Plan with nationwide implemen-
tation of multidisciplinary teams including one-stop clinics
offering quick access in district hospitals.22 Undoubtedly,
PHC physicians play an essential role in the initial manage-
ment of cancer suspicion and diagnosis.3,8,23,24 Although
unreported, the QDU model could successfully overcome the
barriers to rapid diagnosis in patients with unexplained
lymphadenopathy, at least in public health systems like
Spain, where there is often a poor coordination between
primary and hospital care, meaning that, in practice, only
inpatients are prioritized for quick diagnostic testing.6–8,14
Malignancy was promptly diagnosed. The longer mean
time to diagnosis in patients with lymphoma compared with
metastatic lymphadenopathy (7.5 vs 5.4 days, respectively)
is likely explained by the uselessness of FNAC in 6% of
the former patients, who required a biopsy at a later stage.
Overall, these results compare favorably with studies
revealing that time to diagnosis in lymphoma can be
inappropriately lengthy.16,25–28 Furthermore, our mean waits
from diagnosis to first treatment (about 28 days in lym-
phoma and 20 days in metastatic lymphadenopathy) and
from receiving the PHC referral report to first treatment (40
days in lymphoma and approximately 29 days in metastatic
lymphadenopathy) amply complied with UK NHS treatment
waiting time standards (31 days from diagnosis/decision to
treat to first treatment and 62 days from urgent PHC
physician referral to first treatment)18–20 and also with
Spanish Health Ministry targets (30 days from diagnosis to
first treatment).29 Treatment waiting times were longer in
patients with lymphoma as a result of the additional
surgical biopsy performed on all of them.
Is there an advantage of QDU over conventional diagnostic
pathways regarding waiting times in lymphoma and metastatic
lymphadenopathy? Before answering this question, some consid-
erations should be made. Comparing results of cancer waiting
times is usually problematic due to different methods of data
gathering (eg, medical records and surveys), different values (eg,
median or mean), and different time periods.25,28 Despite the
efforts of cancer registries to define and standardize the variables
they gather, there is no general consensus on the indicators and
methods to establish treatment waiting times.4,30 Furthermore, in
numerous countries, including Spain, public health bodies do not
systematically monitor cancer time periods, and studies have
largely been carried out in hospitals4,31 or relied on data from
primary care registries.26,28
Research studies on waiting times in lymphoma are
relatively scarce. Unlike other malignances, the path to
diagnosis can be especially difficult. In the absence of
peripheral lymphadenopathy, clinical presentation may be
imprecise and broad and symptoms may also be seen in
patients with benign disease, purportedly resulting in pro-
tracted diagnostic and treatment waiting times.25,27 A UK
National Institute for Health and Care Excellence guideline
acknowledges that delayed diagnosis in lymphoma may be a
consequence of wrong referral pathways from PHC.32,33
After performing a literature review, our predefined
diagnostic waiting times in lymphoma were shorter than those
reported in 3 research studies.10,26,27 In the aforementioned study
by Chau et al10 of a quick lymph node diagnostic clinic, the
median time from the first clinic visit to diagnosis was 21 days
in HL and 24 days in diffuse large B-cell lymphoma (DLBCL)
(median of 7 days in all lymphoma types in our study). Two
studies using a conventional pathway (ie, PHC referral to
hospital) revealed a median time from referral to diagnosis of
55 days in all lymphoma types27 (median of 11.2 days in our
study) and a mean time from first hospital visit to diagnosis of
14.5 days in NHL26 (mean of 7.5 days in all lymphoma types in
our study), respectively. With regard to treatment waiting times,
in the study by Chau et al,10 the median time from receiving
initial referral report to the first treatment was 35 days in HD
and 39 days in DLBCL (median of 39.1 days in all lymphoma
types in our study). No other studies have examined the
treatment waiting times in lymphoma using our predefined
times. Although prehospital delays (eg, patient and PHC delays)
were not analyzed in our study, an article published by Danish
researchers16 revealed a median time from first PHC physician
investigation to first treatment of 60 days in NHL.
Unlike lymphoma, no previous studies have explicitly
reported the waiting times in metastatic lymphadenopathy
as we did. Nevertheless, some authors have described the
specific times in local and disseminated disease among
patients hospitalized for diagnosis and treatment of solid
cancer. A Spanish study of 1023 patients diagnosed with
the 6 most incident cancers in 22 hospitals found shorter
times from diagnosis to first treatment in disseminated
than in local stage, with median times varying according
to the cancer site. For instance, in disseminated disease, it
was 17.5 days in breast cancer, 20 days in colorectal
cancer, and 24 days in lung cancer.31 Our median time
from diagnosis to first treatment in metastatic lymph-
adenopathy was 18.7 days. In another Spanish study of
7223 patients diagnosed with different solid malignancies
in a public hospital in Barcelona, median times from
diagnosis to first treatment also varied depending on
tumor location (eg, 12 days in stage IV lung cancer,
14 days in stage IV colorectal cancer, and 25 and 18 days
in stage III and IV breast cancer, respectively).4 Of
concern, a recent report from the Spanish Health Ministry
revealed that, during 2009, the mean time from diagnosis
to first treatment surpassed 30 days (the standard target)
in 44% of breast cancer patients (any stage other than in
situ) from 93 hospitals and in 55% of colorectal cancer
patients (any stage other than in situ) from 97 hospitals.29
Undeniably, the collaboration between the QDU and the
cytopathology unit, with a first clinical selection of candidates
to FNAC by the QDU internist and the cytopathologists’
systematic approach, was essential to achieving these waiting
times. As it is well known, FNAC is a quick, economical, and
minimally invasive method for the diagnosis of a range of
benign and malignant epithelial processes and is also used to
assess lymphoma recurrence.34–36 The reported accuracy of
FNAC for diagnosing metastatic lymphadenopathy may be
>90% using only conventional morphology,10,36 and, when
combined with immunocytochemistry, the tumor site may be
identified in a significant proportion of cases, up to 86% in a
recent study,37 in line with our results.
Regarding lymphoma, although its primary diagnosis
and classification is conventionally made by biopsy, in the
last decade and a half, several studies have reported that
FNAC can also have a relatively high diagnostic sensitivity
and specificity, mainly in NHL, when using the cytomor-
phology/immunophenotyping combination.34,36–43 In some
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instances, the reported diagnostic rates of this combination
(assisted sometimes by cytogenetic and/or molecular stu-
dies) have led authors to claim that FNAC may not be
necessarily accompanied by histopathology, whereas others
have stated that NHL may be accurately sub-
typed.34,36,39,40,42,43 However, diagnosis of lymphoma by
FNAC remains controversial and there is a consensus
among oncologists and hematopathologists that histo-
pathology is essential to drive therapeutic decisions.40,44,45
Not only some lymphomas are difficult to evaluate using
FNAC (eg, HL [particularly lymphocyte-depleted classical
HL, due to the scarcity of Reed–Sternberg cells and the
mixture of nonmalignant cells], T-cell-rich B-cell lym-
phoma, and T-cell NHL45] but also diagnostic limitations
include insufficient material to perform flow cytometry or
additional stains, grading, sampling error, and, in general,
loss of architecture.37,40,45,46 Although false positives are
uncommon (0.2%–2.4%), a relatively high rate of false
negatives represents another drawback of FNAC in clinical
practice.10,45–47 For this reason, the low rate of false
negatives in our study (1.3%) compared with others was
particularly encouraging.34,36,37,39,42,45,47,48
The lack of false positives and, especially, the low
proportion of false negatives is justified by the systematic
approach performed by experienced cytopathologists and
further examination of specimens by a specialized immuno-
phenotyping unit, reflecting an enhanced quality of FNAC
diagnostic samples. The presence of both the cyto-
pathologist and the patient in a separate, sufficiently
equipped cytology room (intended for FNAC studies
exclusively) where samples are carefully checked and
further sampling performed as necessary helps also to
retrieve optimal specimens.
In our experience, a skilled cytopathologist performing
an FNAC of a clinically likely malignant lymphadenopathy
should be able, in most cases, to quickly differentiate a
metastatic tumor from lymphoma. Based on our results,
patients with unexplained peripheral lymphadenopathy
whose characteristics make the clinician suspect malignancy
can safely undergo a rapid FNAC first. If solid
malignancy is confirmed, the patient should be immediately
referred to the oncologist, who may then complete the
staging of disease and start treatment, although, in some
cases, he or she may order an additional histological study
for molecular diagnosis. If lymphoma is reported by FNAC,
even though a biopsy will be necessary in most cases,45 the
clinician may immediately refer the patient to the hemato-
logist while simultaneously ordering an excisional biopsy.
The hematologist may then have the biopsy report earlier
than if it is he or she who first orders the procedure, and
may complete the staging and start treatment.
Perhaps the most important study limitation is that ours
was a single-institution study. Yet the unit attended patients
from 12 PHC centers and the sample evaluated is represen-
tative of other QDU populations in Spain.6–9 In addition,
owing to the relatively small sample (n¼ 81) and short time
elapsed since the creation of our QDU (2005) or the onset
of the study (2006), it is premature to assess any survival
benefit (eg, improvement in 5-years overall survival) of the
model in patients with lymphoma as a result of shortened
waiting times. Of note, however, even though it may be
intuitively expected that earlier diagnosis leads to improved
outcomes, the impact of delayed presentation and diagnosis
of lymphoma on survival is uncertain.27,32,33,49,50
CONCLUSION
A distinct internal medicine outpatient quick diagnostic
clinic allows an expeditious, agile, and prearranged system
to diagnose unexplained peripheral lymphadenopathy, most
notably malignant lymphadenopathy. Because of the close
collaboration with the cytopathology unit and the FNAC
methodical approach, the diagnostic and treatment waiting
times of patients with malignancy fulfilled national and
international time frame standards. In the case of lymphoma,
diagnostic waiting times were shorter than those reported in
studies using conventional diagnostic pathways. The reli-
ability and accuracy of FNAC may be high provided that the
samples are handled by expert cytopathologists and further
tested by someone skilled in immunocytochemistry and flow
cytometry. This particular diagnostic delivery unit could help
overcome the difficulties facing PHC, ED, and other
physicians when trying to provide rapid access to diagnostic
tests to patients with troublesome lymphadenopathy.
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